These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

765 related items for PubMed ID: 19254788

  • 1. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
    Kanis JA, Johansson H, Oden A, McCloskey EV.
    Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
    Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA.
    J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
    [Abstract] [Full Text] [Related]

  • 3. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
    Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.
    Arch Intern Med; 2008 Dec; 157(22):2617-24. PubMed ID: 9531231
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example.
    Ström O, Borgström F, Kleman M, McCloskey E, Odén A, Johansson H, Kanis JA.
    Bone; 2010 Aug; 47(2):430-7. PubMed ID: 20493983
    [Abstract] [Full Text] [Related]

  • 6. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [Abstract] [Full Text] [Related]

  • 7. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ.
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
    Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z, Luisetto G, Padrino JM, Doyle D, Prince R, Fardellone P, Sorensen OH, Meunier PJ.
    J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373
    [Abstract] [Full Text] [Related]

  • 10. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
    Qu Y, Wong M, Thiebaud D, Stock JL.
    Curr Med Res Opin; 2005 Dec; 21(12):1955-9. PubMed ID: 16368046
    [Abstract] [Full Text] [Related]

  • 11. An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®.
    Kaufman JM, Palacios S, Silverman S, Sutradhar S, Chines A.
    Osteoporos Int; 2013 Oct; 24(10):2561-9. PubMed ID: 23595562
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older.
    Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM, Hoszowski K, Varela AR, Fiore C, Brixen K, Reginster JY, Boonen S.
    J Bone Miner Res; 2006 Jul; 21(7):1113-20. PubMed ID: 16813532
    [Abstract] [Full Text] [Related]

  • 17. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
    Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C.
    Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
    [Abstract] [Full Text] [Related]

  • 18. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP.
    Arch Intern Med; 2003 Oct 13; 163(18):2237-46. PubMed ID: 14557222
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.
    Donaldson MG, Palermo L, Ensrud KE, Hochberg MC, Schousboe JT, Cummings SR.
    J Bone Miner Res; 2012 Aug 13; 27(8):1804-10. PubMed ID: 22492479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.